AMGN241220C295000
- 0.01
- -0.02-66.67%
Amgen Newsroom
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $350
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating
UBS Cuts Price Target on Amgen to $280 From $326, Maintains Neutral Rating
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Oppenheimer Remains a Buy on Amgen (AMGN)
Amgen Analyst Ratings
Evercore Maintains Amgen(AMGN.US) With Buy Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN)
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $360
Amgen Analyst Ratings
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $305 to $380
Deutsche Bank Adjusts Price Target on Amgen to $285 From $305, Maintains Hold Rating
Amgen's MariTide Phase 2 Success Drives Buy Rating Amid Promising Obesity Treatment Prospects
Citigroup Adjusts Price Target on Amgen to $310 From $335, Neutral Rating Maintained
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's